Rob de ReeOperating Partner

Rob has over 25 years’ experience in the pharmaceutical and medtech industry in sales, marketing, business development and general management. Rob started his career in pharma in 1991 at the cardiovascular division of Byk Gulden in different roles in sales and marketing. Rob joined Medtronic international in 1996 where he was responsible for building the European venture business for the Octopus and other minimally invasive cardiac surgery products. During his 9-year tenure at Medtronic Rob moved to the Cardiac Rhythm Management division and in 2004 he was appointed European marketing director located in the Medtronic European headquarters in Switzerland. Rob moved to Crucell (senior Business Development Director) after which he joined the startup company BMEYE (hemodynamic monitoring) in June 2007 as the VP Sales & Marketing and was appointed CEO in January 2008.Under his leadership, BMEYE was successfully sold to Edwards Lifesciences in 2012. After a transition phase Rob left Edwards and joined Dezima Pharma as the CEO. Dezima pharma was sold to Amgen in October 2015 for a total deal value of up to $ 1.5 billion. Rob holds a MSc in pharmacy from the University of Groningen.

Rob joined BioGeneration in September 2016 as operating partner and as shall serve in board and interim management positions in the fund’s portfolio companies, leveraging Rob’s considerable experience and network in the industry, and further support and advise the investment team.

Telephone +31 35 - 699 3000
E-mail adress
Desktop versie